Search

Displaying results 4021 - 4030 of 5897 in total
  1. Drug

    Phenazocine

    go.drugbank.com/drugs/DB13606
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. … The combination of selectivity for the beta form of the receptor, liver targeting and other structural characteristics that limit extra-hepatic activity is designed to provide significant efficacy while

  3. Drug

    Recombinant Bacterial ACE2 Receptors-like Enzyme

    go.drugbank.com/drugs/DB15741
    Investigational

    ._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels.

  4. Drug

    Alcuronium

    go.drugbank.com/drugs/DB13648
    Experimental

    A non-depolarizing skeletal muscle relaxant similar to [tubocurarine]. It is used as an anesthesia adjuvant.

  5. Drug

    Propionate ion

    go.drugbank.com/drugs/DB19384
    Investigational

    Propionate ion is under investigation in clinical trial NCT00846326 (Preventing Tolerance to Oxymetazoline in Allergic Rhinitis).

  6. Drug

    NRP290

    go.drugbank.com/drugs/DB06383
    Experimental

    NRP290 is a hydrocodone derivative under investigation for the treatment of pain (moderate to moderately severe).

  7. Drug

    Clorindione

    go.drugbank.com/drugs/DB13275
    Experimental

    Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans.

  8. Drug

    Lanifibranor

    go.drugbank.com/drugs/DB14801
    Investigational

    Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).

  9. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.

  10. Drug

    Veverimer

    go.drugbank.com/drugs/DB18977
    Investigational

    Veverimer is under investigation in clinical trial NCT03390842 (Long-term Safety Extension to Study TRCA-301).